Abstract Background The Atopic Dermatitis (AD) TREATgermany registry was initiated by the
German Society for Dermatology (DDG) in 2011 to evaluate the 'real‐life'situation of health …

Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder
characterized by chronic or relapsing eczematous lesions with intense pruritus and …

Design This observational cohort study included patients who attended the National
Expertise Center for Atopic Dermatitis in the University Medical Center Utrecht (UMCU), the …

Background The real-world persistence with dupilumab therapy for atopic dermatitis (AD) is
unknown. Objective To characterize adults with AD who initiated dupilumab and evaluate …

[1] Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ. Omalizumab in
patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br …

Introduction The treatment of severe atopic dermatitis (AD) includes cyclosporine and
recently approved biologics and small molecules. Among these, upadacitinib is a selective …

Epidemiological studies have shown a rise in the prevalence of allergic diseases in India
during the last two decades. However, recent evidence from the Global Asthma Network …

Background Atopic dermatitis (AD) is the leading cause of the global burden from skin
disease; no study has provided global and country-specific epidemiological estimates of AD …

Atopic dermatitis (AD) is an inflammatory skin disease arising from a complex interplay of
genetic, immune, and environmental factors. The development and successful marketing of …

Background Dupilumab, an antibody against interleukin‐4 receptor α, has demonstrated
elegant efficacy and safety profiles in patients with moderate‐to‐severe atopic dermatitis …